Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome.
Publication
, Preprint
Tu, T; Ochoa, A; Sood, A; Drabik, A; Chryst-Stangl, M; Lane, B; Wu, G; Donovan, F; Harper, U; Chandrasekharappa, S; Esezobor, C; Solarin, A ...
August 7, 2025
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Tu, T., Ochoa, A., Sood, A., Drabik, A., Chryst-Stangl, M., Lane, B., … Gbadegesin, R. (2025). Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome. https://doi.org/10.1101/2025.08.01.25332825
Tu, Tiffany, Alejandro Ochoa, Amika Sood, Ashley Drabik, Megan Chryst-Stangl, Brandon Lane, Guanghong Wu, et al. “Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome.,” August 7, 2025. https://doi.org/10.1101/2025.08.01.25332825.
Tu T, Ochoa A, Sood A, Drabik A, Chryst-Stangl M, Lane B, et al. Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome. 2025.
Tu, Tiffany, et al. Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome. 7 Aug. 2025. Pubmed, doi:10.1101/2025.08.01.25332825.
Tu T, Ochoa A, Sood A, Drabik A, Chryst-Stangl M, Lane B, Wu G, Donovan F, Harper U, Chandrasekharappa S, Esezobor C, Solarin A, Hooper D, Sethna C, Amaral S, Kallash M, Rheault M, Verghese P, Dharnidharka V, Salmon E, Weng P, Srivastava T, Seifert ME, Pruette C, Selewski D, Gibson K, Hunley T, Abeyagunawardena A, Thalgahagoda S, Bagga A, Sinha A, Webb N, Greenbaum L, Gharavi A, Kiryluk K, Kretzler M, Guay-Woodford L, Sanna-Cherchi S, Bierzynska A, Koziell A, Welsh G, Saleem M, Rotimi C, Chambers E, Chan C, CureGN Consortium, PNRC Glomerular disease group, CIBMTR/NMDP Consortium, Jackson A, Adeyemo A, Gbadegesin R. Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome. 2025.